>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
川芎嗪洗脱支架预防支架内再狭窄的实验研究
作者:李璇1 陈忠1 马根山1 苏亚民1 顾兴中2 
单位:1.东南大学,临床医学院,江苏,南京,210009; 2.东南大学,机械工程学院,江苏,南京,210096
关键词:川芎嗪 药物洗脱支架 再狭窄 免疫组织化学 
分类号:R815, R541.4
出版年·卷·期(页码):2008·27·第二期(102-105)
摘要:

目的:研究川芎嗪洗脱支架(TES)抑制内膜增生防治再狭窄的效果及其机制.方法:小型猪9只随机分为3组,实验组植入TES(TES组),对照组植入金属裸支架(BMS组)或雷帕霉素洗脱支架(SES组).术后第28天处死动物,组织病理学检测内膜厚度,免疫组织化学法测定增殖细胞核抗原(PCNA),TUNEL法测细胞凋亡,扫描电镜观察内皮细胞的覆盖情况.结果:术后第28天病理学证实,TES组较BMS组管腔面积增加、支架内新生内膜面积和面积再狭窄百分比减小(P<0.05).BMS组较TES组PCNA 细胞阳性率明显增加(P<0.05),TES组较SES组PCNA阳性率增加(P<0.05).TES组较BMS组单位面积内平滑肌细胞 (VSMC)凋亡数明显增加(P<0.05).扫描电镜显示TES组和BMS组28 d血管内皮细胞完全覆盖,SES组基本覆盖,但内膜不平整.结论:TES可以显著抑制VSMC 增殖、迁移并促进VSMC凋亡,但不影响血管内皮愈合,是防治血管再狭窄的新策略.

Objective To assess the preventive effect and mechanism of tetramethylpyrazine(TMP)-eluting stents(TES)on in-stent restenosis in pigs.Methods Nine pigs were randomly divided into TES group,bare-metal stents(BMS) group and sirolimus-eluting stents(SES) group.The TES group was implanted with TES,the BMS group with BMS,the SES group with SES.At the 28th day,animals were executed and neointimal thicknesses,proliferating cell nuclear antigen(PCNA) of vascular smooth muscle cell(VSMC),apoptosis of VSMC were measured.Scan electron microscope was used to observe the covering instances of endothelial cells.Results Comparing with BMS,luminal area was significantly increased in the TES group(P&lt;0.05),while neointimal area and percentage of restenosis were significantly decreased in the TES group(P&lt;0.05).The positive ratio of PCNA of BMS group was higher than that of TES group(P&lt;0.05).The positive ratio of PCNA of TES group was higher than that of SES group.The apoptosis was significantly increased in TES group than that in BMS group(P&lt;0.05).Scan electron microscope indicated complete reendothelialization at the 28th day in BMS and TES groups,but poor endothelium covering in the SES group.Conclusion TES can inhibit the hyperplasia and migration of VSMC and increase VSMC apoptosis,but it has no effect on the healing of endothelium.TES is a promising and new strategy in preventing restenosis.

参考文献:

[1] PFISTERER M, BRUNNER-LA H P, BUSER P T. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drug-eluting vs.bare-metal stents. 2006(12). doi:10.1016/j.jacc.2006.10.026
[2] 袁晋青, 高润霖, 宋来凤. 小型猪冠状动脉置入过大直径支架建立再狭窄动物模型. 中国循环杂志1999(5)
[3] 刘玉洁, 孙根义, 刘志勇. 川芎嗪防治冠心病经皮冠状动脉介入术后再狭窄的临床研究. 中国心血管杂志2004(2). doi:10.3969/j.issn.1007-5410.2004.02.005
[4] 陈立娟, 马根山, 陈忠. 川芎嗪涂层支架生物相容性的实验研究. 现代医学2006(6). doi:10.3969/j.issn.1671-7562.2006.06.001
[5] 冯津萍, 陈星, 陈敏荔. 血管内皮损伤后血管平滑肌细胞增殖的机制. 中华急诊医学杂志2005(9)
[6] 冯津萍, 卢奕, 陈星. 川芎嗪对血管平滑肌细胞增殖抑制作用的探讨. 中草药2007(1)
[7] 李映红, 吴正治, 郑红花. 从CaN信号通路探讨川芎嗪对AngⅡ诱导的大鼠VSMCs增殖的抑制作用及机制. 上海中医药杂志2006(5). doi:10.3969/j.issn.1007-1334.2006.05.025
[8] 张健, 蔡生业, 姚成芳. 川芎嗪对PDGF-BB诱导的大鼠血管平滑肌细胞增殖和骨桥蛋白mRNA表达的影响. 山东中医药大学学报2005(3). doi:10.3969/j.issn.1007-659X.2005.03.024
[9] LUSCHER T F, STEFFEL J, EBERLI F R. Drug-eluting stent and coronary thrombosis:biological mechanisms and clinical implications. 2007. doi:10.1161/CIRCULATIONAHA.106.675934
[10] 吴红金, 吕俊萍, 马增春. 川芎嗪对培养人脐静脉内皮细胞基因表达谱的影响. 中国实验方剂学杂志2005(3). doi:10.3969/j.issn.1005-9903.2005.03.018
[11] 林蓉, 刘俊田, 李旭. 川芎嗪对血管内皮细胞损伤的保护作用. 中国药理学与毒理学杂志2000(6)
[12] 何维来, 陈如坤, 周汝元. 川芎嗪对结扎犬LAD损伤冠脉内皮及心肌的保护作用. 第四军医大学学报2005(23)
[13] SHEU J R, KAN Y C, HUNG W C. Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. 1997(3). doi:10.1016/S0049-3848(97)00253-3
[14] SHEU J R, KAN Y C, HUNG W C. The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase. 2000(8). doi:10.1016/S0024-3205(0)00686-X
[15] 吴文元. 川芎嗪治疗周围动脉粥样硬化闭塞症疗效观察. 实用中医药杂志2002(8). doi:10.3969/j.issn.1004-2814.2002.08.002

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405867 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364